Mitoxantrone drug data and news

Mitoxantrone drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.

Generic name

Mitoxantrone

Brand Names/Synonyms

CCRIS 7604; CHEMBANK1135; DHAD; DHAQ; Dhaq Hcl; Dihydroxyanthraquinone; Immunex; M6545; Mitox; Mitoxanthrone; Mitoxantron; Mitoxantrona [Inn-Spanish]; Mitoxantrone; Mitoxantrone 2hcl; Mitoxantrone Dihydrochloride; Mitoxantrone Hcl; Mitoxantrone Hydrochloride; Mitoxantronum [Inn-Latin]; Mitozantrone; Mitozantrone Hydrochloride; Novantron; Novantrone

Indication

For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis

Sponsored links

Description

Not Available

Pharmacology

Mitoxantrone has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2.

Mechanism Of Action

Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA. It has a cytocidal effect on both proliferating and nonproliferating cultured human cells, suggesting lack of cell cycle phase specificity.

Mitoxantrone News
(When available)

Two-Day Tysabri Hearing Drawing Intense Attention Mar 3, 2006
1a, from Serono SA). An immunosuppressant, Novantrone (mitoxantrone, also from Serono), is used as well. Jeffrey expressed concern ... - BioWorld Online (subscription),

New studies highlight the benefit of anti-MS drug Mar 2, 2006
Interferon-beta, a cytokine, has been used for some years as a therapy, along with other drugs such as glatiramer acetate and mitoxantrone. ... - Ars Technica,

Taxotere® and Novantrone® Sequence Evaluated as Initial ... Feb 22, 2006
...published in the journal Cancer, initial chemotherapy treatment with the agent Taxotere® (docetaxel) followed by Novantrone® (mitoxantrone) appears more ... - Cancer Consultants (press release),

YM BioSciences reports second quarter 2006 operational and ... Feb 10, 2006
...is now expected to be advanced with the first randomized trial in this indication and is expected to compare a standard of care mitoxantrone/prednisone used in ... - MSN Money

Flat sales in Q4 for Serono; no word on buyer Feb 6, 2006
...the quarter, but the fall-off in sales accelerated for two of Serono's other products, Serostim (somatropin) for wasting and Novantrone (mitoxantrone) for MS ... - Pharma Times (subscription),

Xanthus' Symadex(TM) shows Remyelination in Multiple Sclerosis ... Feb 13, 2006
Symadex was developed to deliver efficacy comparable to the anthracenediones (eg, Novantrone(R) (mitoxantrone)), but with a molecular scaffold intended to ... - Canada NewsWire (press release),

Dosage Forms

Solution

Drug_Category

Antineoplastic Agents; Analgesics; ATC:L01DB07

Absorption

poor (oral)

Interactions

-->Interactions for Mitoxantrone:

Mitoxantrone and its metabolites are excreted in bile and urine, but it is not known whether the metabolic or excretory pathways are saturable, may be inhibited or induced, or if mitoxantrone and its metabolites undergo enterohepatic circulation. To date, post-marketing experience has not revealed any significant drug interactions in patients who have received NOVANTRONEâ for treatment of cancer. Information on drug interactions in patients with multiple sclerosis is limited.

Following concurrent administration of NOVANTRONEâ with corticosteroids, no evidence of drug interactions has been observed.

Toxicity

severe leukopenia with infection. LD50=mg/kg(orally in rat)

Organisms Affected

Humans and other mammals

Chemical IUPAC Name

1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]-anthracene-9,10-dione

Chemical Formula

C22H28N4O6

Molecular Weight

444.481 g/mol

Smiles String

C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO

Melting Point

Not Available

Water Solubility

Not Available

State

sterile, nonpyrogenic, dark blue aqueous solution

LogP/Hphobicity

-0.924

Isoelectric Point

Not Available

Biotransformation

Hepatic

Half Life

75 hours

Protein Binding [%]

78%

RxList Link

RXlist

Sponsored links

Drug Reference

http://www.drugs.com/cons/Mitoxantrone.html
http://www.rxlist.com/cgi/generic2/mitoxantrone.htm

Drug Type

Approved Drug

Accession No

APRD00371

CAS Registry Number

65271-80-9

KEGG Compound ID

C11195

PubChem ID

SID:282102

PharmGKB ID

PA450526

SwissProt ID

Not Available

GenBank ID

Not Available

Drug ID Number [DIN]

2244614